At BioSynaptica, we believe in science as a central tool to improve people’s quality of life.
Our development focuses on the generation of an innovative erythropoietin-based neurotherapeutic to meet the needs of millions of people around the world who suffer from central nervous systems conditions like Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, stroke, among others.
Human erythropoietin (hEPO) is a widely used biotherapeutic for anemia treatment because it stimulates red blood cells production. In addition, hEPO has neuroprotective and neuroplastic activity. Nevertheless, when it is used as a neuropharmaceutical in patients who do not suffer from anemia, it causes erythropoietic activity-associated side effects.
Our team achieved a great milestone: modifying the hEPO molecule, nullifying its undesired effect and preserving its neuroprotective and neuroplastic capacity. This important breakthrough improves the properties of hEPO for use in the treatment of chronic diseases.